Clinical Trial

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Study acronym: TRuE-VIP1
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2026 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Protocol Amendment History 1 change
notable Trial sites reduced: 101 -> 98 locations 2026-07-24
Trial Details
NCT Number NCT06548360
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 180 participants
Start Date 2025-01-24
Primary Completion 2026-08-10 (estimated)
Study Completion 2027-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-23